DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
EP0994862B1
(en)
|
1997-07-11 |
2005-06-01 |
SmithKline Beecham plc |
Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
|
EP1053227B1
(en)
|
1998-01-29 |
2008-11-05 |
Amgen Inc. |
Ppar-gamma modulators
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
US6194410B1
(en)
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9818916D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
AU2441801A
(en)
*
|
1999-12-21 |
2001-07-03 |
Smithkline Beecham Corporation |
Urotensin-ii receptor antagonists
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
AU2001288053A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
EP1341783A1
(en)
*
|
2000-11-21 |
2003-09-10 |
Smithkline Beecham Plc |
Isoquinoline derivatives useful in the treatment of cns disorders
|
KR20030064852A
(ko)
|
2000-12-22 |
2003-08-02 |
이시하라 산교 가부시끼가이샤 |
아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제
|
EP1389194A2
(en)
*
|
2001-04-27 |
2004-02-18 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of bace
|
WO2002089785A1
(en)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
US20040198979A1
(en)
*
|
2001-05-07 |
2004-10-07 |
Dashyant Dhanak |
Sulfonamides
|
US6743796B2
(en)
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
JP2004529168A
(ja)
*
|
2001-05-07 |
2004-09-24 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
AR033879A1
(es)
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
JP2005508852A
(ja)
*
|
2001-05-07 |
2005-04-07 |
スミスクライン・ビーチャム・コーポレイション |
スルホンアミド
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
BR0209558A
(pt)
*
|
2001-05-11 |
2004-04-20 |
Biovitrum Ab |
Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
|
KR100922486B1
(ko)
*
|
2001-05-11 |
2009-10-20 |
바이오비트럼 에이비(피유비엘) |
비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한신규한 아릴술폰아미드 화합물
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
KR100600240B1
(ko)
|
2001-06-07 |
2006-07-13 |
에프. 호프만-라 로슈 아게 |
5-ht6 수용체 친화도를 갖는 신규한 인돌 유도체
|
WO2002100822A1
(en)
|
2001-06-11 |
2002-12-19 |
Biovitrum Ab |
Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
|
BR0210411A
(pt)
|
2001-06-15 |
2004-08-17 |
Hoffmann La Roche |
Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
|
US6727264B1
(en)
*
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
WO2003013510A1
(en)
*
|
2001-08-07 |
2003-02-20 |
Smithkline Beecham P.L.C. |
3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
EP1423106B1
(en)
|
2001-08-10 |
2008-12-17 |
F. Hoffmann-La Roche Ag |
Arylsulfonyl derivatives with 5-ht 6 receptor affinity
|
WO2003022272A1
(fr)
*
|
2001-09-05 |
2003-03-20 |
Eisai C0. Ltd. |
Agents stimulant l'appetit et remedes contre l'anorexie
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
DE60232173D1
(de)
*
|
2001-11-09 |
2009-06-10 |
Biovitrum Ab Publ |
Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
|
US7074788B2
(en)
|
2001-11-22 |
2006-07-11 |
Biovitrum Ab |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
RS44304A
(en)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
|
EP1453514B1
(en)
*
|
2001-11-30 |
2007-07-18 |
F. Hoffmann-La Roche Ag |
Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
|
EP1471912A1
(en)
*
|
2002-02-05 |
2004-11-03 |
Glaxo Group Limited |
Method of promoting neuronal growth
|
WO2003066604A2
(en)
*
|
2002-02-05 |
2003-08-14 |
Novo Nordisk A/S |
Novel aryl- and heteroarylpiperazines
|
KR20040081201A
(ko)
*
|
2002-02-13 |
2004-09-20 |
글락소 그룹 리미티드 |
항정신병제로서 벤젠술폰아미드 유도체
|
US20050085461A1
(en)
*
|
2002-02-13 |
2005-04-21 |
Cooper David G. |
Benzenesulfonamide derivatives
|
DE60304695T2
(de)
*
|
2002-02-13 |
2006-09-21 |
Glaxo Group Ltd., Greenford |
7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems
|
US7452888B2
(en)
|
2002-03-27 |
2008-11-18 |
Glaxo Group Limited |
Quinoline derivatives and their use as 5-ht6 ligands
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
UA76877C2
(uk)
*
|
2002-05-13 |
2006-09-15 |
Ф.Хоффманн-Ля Рош Аг |
Похідні бензоксазину як 5-нт6 модулятори і їх застосування
|
US7943639B2
(en)
*
|
2002-06-20 |
2011-05-17 |
Proximagen Limited |
Compounds
|
EP1897876A3
(en)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
|
EA008835B1
(ru)
*
|
2002-06-20 |
2007-08-31 |
Биовитрум Аб |
Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
|
RU2324693C2
(ru)
|
2002-10-18 |
2008-05-20 |
Ф.Хоффманн-Ля Рош Аг |
4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6
|
WO2004043369A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Smithkline Beecham Corporation |
Sulfonamides
|
AU2003295408A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
EP1599468B1
(en)
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
JP2006518718A
(ja)
*
|
2003-02-13 |
2006-08-17 |
ランクセス ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
光学データ記録媒体の情報層における吸光性化合物としての金属錯体
|
AU2004212985B2
(en)
*
|
2003-02-20 |
2010-10-14 |
Encysive Pharmaceuticals Inc. |
Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
|
TWI289141B
(en)
*
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
WO2004087654A2
(en)
*
|
2003-03-31 |
2004-10-14 |
Janssen Pharmaceutica N.V. |
Phospholipase c inhibitors for use in treating inflammatory disorders
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
TW200523253A
(en)
|
2003-07-22 |
2005-07-16 |
Arena Pharm Inc |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
SE0303480D0
(sv)
*
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
KR20060127886A
(ko)
*
|
2003-12-19 |
2006-12-13 |
바이오비트럼 에이비 |
5-ht6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체
|
EP1778679A1
(en)
|
2004-07-28 |
2007-05-02 |
Glaxo Group Limited |
Piperazine derivatives useful for the treatment of gastrointestinal disorders
|
ES2348467T3
(es)
*
|
2004-09-30 |
2010-12-07 |
F. Hoffmann-La Roche Ag |
Derivados y usos de la benzoxazina y la quinoxalina.
|
WO2006040176A1
(en)
|
2004-10-14 |
2006-04-20 |
Abbott Gmbh & Co. Kg |
Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
|
ES2364488T3
(es)
|
2004-10-14 |
2011-09-05 |
ABBOTT GMBH & CO. KG |
Compuestos heterocíclicos adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina.
|
WO2006062481A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
|
EP1676841A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
|
WO2006075808A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Inje University |
Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease
|
ES2375929T3
(es)
|
2005-07-04 |
2012-03-07 |
High Point Pharmaceuticals, Llc |
Antagonistas del receptor histamina h3.
|
CN101258144B
(zh)
|
2005-08-12 |
2012-05-30 |
苏文生命科学有限公司 |
作为功能性5-ht6配体的氨基芳基磺酰胺衍生物
|
WO2007020654A1
(en)
|
2005-08-16 |
2007-02-22 |
Suven Life Sciences |
An improved process for the preparation of losartan
|
US20100048713A1
(en)
*
|
2006-01-06 |
2010-02-25 |
Aarhus Universitet |
Compounds acting on the serotonin transporter
|
US7713978B2
(en)
|
2006-03-31 |
2010-05-11 |
Nigel Paul King |
Compounds
|
EP2074110A1
(en)
|
2006-04-19 |
2009-07-01 |
Abbott GmbH & Co. KG |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
|
CA2648891A1
(en)
|
2006-04-19 |
2007-10-25 |
Abbott Gmbh & Co. Kg |
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
|
CA2653062A1
(en)
|
2006-05-23 |
2007-11-29 |
Transtech Pharma, Inc. |
6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
|
WO2007137968A1
(en)
|
2006-05-29 |
2007-12-06 |
High Point Pharmaceuticals, Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
CA2669117A1
(en)
|
2006-10-26 |
2008-05-02 |
Gary A. Flynn |
Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
|
US8470830B2
(en)
|
2007-01-08 |
2013-06-25 |
Suven Life Sciences Limited |
5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
|
JP5208963B2
(ja)
*
|
2007-01-10 |
2013-06-12 |
エフ.ホフマン−ラ ロシュ アーゲー |
キマーゼ阻害剤としてのスルホンアミド誘導体
|
WO2008116833A1
(en)
|
2007-03-23 |
2008-10-02 |
Abbott Gmbh & Co. Kg |
Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
WO2008136017A1
(en)
|
2007-05-03 |
2008-11-13 |
Suven Life Sciences Limited |
Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
EP2016943B1
(en)
*
|
2007-07-19 |
2011-02-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
|
ES2370680T3
(es)
|
2007-10-26 |
2011-12-21 |
Suven Life Sciences Limited |
Compuestos de aminoarilsulfonamida y su empleo como ligandos de 5-ht6.
|
PA8802201A1
(es)
*
|
2007-11-02 |
2009-06-23 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
|
WO2009074607A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
JP2011524365A
(ja)
*
|
2008-06-11 |
2011-09-01 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
マラリアの処置に有用な化合物および組成物
|
MX2011002884A
(es)
*
|
2008-09-17 |
2011-04-21 |
Suven Life Sciences Ltd |
Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
|
US8318725B2
(en)
|
2008-09-17 |
2012-11-27 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
CN102459199A
(zh)
*
|
2009-04-30 |
2012-05-16 |
雅培股份有限两合公司 |
适于治疗响应于5-羟色胺5-ht6受体调节的病症的苯磺酰苯胺化合物
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
ES2536779T3
(es)
|
2009-04-30 |
2015-05-28 |
Abbvie Deutschland Gmbh & Co Kg |
Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6
|
US8183237B2
(en)
|
2009-04-30 |
2012-05-22 |
Abbott Laboratories |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
SG181992A1
(en)
|
2010-01-05 |
2012-08-30 |
Suven Life Sciences Ltd |
Sulfone compounds as 5-ht6 receptor ligands
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
MX2014011315A
(es)
|
2012-03-20 |
2014-10-17 |
Adamed Sp Zoo |
Derivados de sulfonamida de bencilamina para el tratamiento de enfermedades del sistema nervioso central.
|
TR201911151T4
(tr)
|
2013-03-14 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
|
RU2688161C2
(ru)
|
2013-07-25 |
2019-05-20 |
Университет Ягеллоньски |
Пирролохинолиновые производные в качестве 5-нт6 антагонистов, способ их получения и применение
|
WO2015158313A1
(en)
|
2014-04-19 |
2015-10-22 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
MX2021011472A
(es)
|
2015-01-06 |
2022-08-17 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
MX2017016413A
(es)
|
2015-06-12 |
2018-08-01 |
Axovant Sciences Gmbh |
Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
|
PL3310760T3
(pl)
|
2015-06-22 |
2023-03-06 |
Arena Pharmaceuticals, Inc. |
Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
|
CA2992518A1
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
WO2019180176A1
(en)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition for the treatment of schizophrenia and/or psychosis
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|